A personalized strategy of dose-escalated radiotherapy (RT) for bladder cancer had a low rate of severe late toxicity and ...

As Roche comes under competitive pressure on its breast cancer business, the Swiss company hopes a new drug will add a ...

We’ve rounded up the best, expert-recommended products to treat hyperpigmentation in dark skin, including cleansers, serums, ...

Roche (RHHBY) has received FDA approval for its drug Itovebi in combination with two other drugs for the treatment of breast ...

Novartis' Piqray/Vijoice (alpelisib) is the only PIK3CA inhibitor to have reached the market for breast cancer, having been ...

With the regulatory approval for advanced breast cancer, Roche’s inavolisib is a potential challenger to Novartis’ PI3K ...

The park in central Wisconsin is still closed to hikers days after a fire damaged the stairway that leads to the top of Roche ...

RHHBY obtains FDA approval for Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.

The US FDA approved Itovebi in combination with Pfizer’s Ibrance and AstraZeneca’s Faslodex for certain breast cancer ...

Some trails in the park in central Wisconsin reopened Friday to hikers days after a fire damaged stairway that leads to the ...

A nonprofit organization established a working group of 12 presidents to discuss challenges unique to small liberal arts ...

Patients with inflammatory bowel disease (IBD) who initially responded to the investigational monoclonal antibody ...